Merck & Co., Inc SC TO-T/A, filed Jan 16, 2020
Merck & Co., Inc. (MRK)
SC TO-T/A
2020-01-16
View Original
Added on
October 17, 2026
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE TO
(Rule 14d-100)
TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934
Amendment No. 5
ARQULE, INC.
(Name of Subject Company (Issuer))
Argon Merger Sub, Inc.
a wholly-owned subsidiary of
Merck Sharp & Dohme Corp.
(Names of Filing Persons (Offerors))
Common Stock, par value $0.01 per share
(Title of Class of Securities)
04269E107
(CUSIP Number of Class of Securities (Underlying Common Stock))
Geralyn S. Ritter
Senior Vice President and Corporate Secretary Merck & Co., Inc.
2000 Galloping Hill Road Kenilworth, NJ 07033
(908) 740-4000
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Persons)
Copies to:
Catherine J. Dargan, Esq.
Michael J. Riella, Esq.
Covington & Burling LLP
One CityCenter
850 Tenth Street, NW
Washington, DC 20001-4956
+1 (202) 662 6000
Calculation of Filing Fee
|
Transaction Valuation*
|
Amount of Filing Fee**
|
|
$2,774,378,700.00
|
$360,114.36
|
| * |
Estimated solely for purposes of calculating the filing fee. This calculation is based on the offer to purchase all of the issued and outstanding shares of common stock, par value $0.01 per share, of ArQule,
Inc. (“ArQule”), at a purchase price of $20.00 per share, net to the seller in cash, without interest and less any applicable tax withholding. As of December 12, 2019 (the most recent practicable
date): (i) 120,873,271 shares of ArQule common stock were issued and outstanding, (ii) no shares of ArQule common stock were held by ArQule in its treasury, (iii) 12,469,512 shares of ArQule common stock were subject to outstanding ArQule
stock options, (iv) no shares of ArQule common stock were subject to outstanding ArQule restricted stock unit awards, (v) warrants to purchase an aggregate of 5,361,556 shares of ArQule common stock were outstanding, and (vi) rights to
purchase a maximum of 14,596 shares of ArQule common stock during the final offering period were outstanding under ArQule’s 2018 Employee Stock Purchase Plan.
|
| ** |
The filing fee was calculated in accordance with Rule 0-11 under the Securities Exchange Act of 1934, as amended, and Fee Rate Advisory No. 1 for Fiscal Year 2020, issued August 23, 2019, by multiplying the
transaction value by 0.0001298.
|
| ☒ |
Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement
number, or the form or schedule and the date of its filing.
|
|
Amount Previously Paid: $360,114.36
|
Filing Party: Argon Merger Sub, Inc. and Merck Sharp & Dohme Corp.
|
|
Form or Registration No.: Schedule TO-T
|
Date Filed: December 17, 2019
|
| ☐ |
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
|
Check the appropriate boxes below to designate any transactions to which the statement relates:
| ☒ |
Third-party tender offer subject to Rule 14d-1.
|
| ☐ |
Issuer tender offer subject to Rule 13e-4.
|
| ☐ |
Going-private transaction subject to Rule 13e-3.
|
| ☐ |
Amendment to Schedule 13D under Rule 13d-2.
|
Check the following box if the filing is a final amendment reporting the results of the tender offer: ☒
If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:
| ☐ |
Rule 13e-4(i) (Cross-Border Issuer Tender Offer)
|
| ☐ |
Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)
|
This Amendment No. 5 (this “Amendment”) amends and supplements the Tender Offer Statement on Schedule TO filed with the Securities and Exchange Commission on December 17, 2019
(together with any amendments and supplements thereto, the “Schedule TO”), by Argon Merger Sub, Inc., a Delaware corporation (“Purchaser”) and wholly-owned subsidiary of
Merck Sharp & Dohme Corp., a New Jersey corporation (“Parent”), and Parent. This Schedule TO relates to the offer by Purchaser to purchase all of the outstanding shares of common stock, par value, $0.01 per
share (the “Shares”), of ArQule, Inc., a Delaware corporation (“ArQule”), at a purchase price of $20.00 per Share (the “Offer Price”),
net to the seller in cash, without interest and less any applicable tax withholding, on the terms and subject to the conditions set forth in the Offer to Purchase and in the related Letter of Transmittal, copies of which are attached to the Schedule
TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively.
Except as otherwise set forth in this Amendment, the information set forth in the Schedule TO remains unchanged and is incorporated herein by reference to the extent relevant to the items in this Amendment. Capitalized
terms used but not defined herein have the meanings ascribed to them in the Schedule TO.
Items 1-9; 11.
The Offer to Purchase and Items 1 through 9 and Item 11 of the Schedule TO, to the extent such items incorporate by reference the information contained in the Offer to Purchase, are hereby amended and supplemented as
follows:
“The Offer and related withdrawal rights expired as scheduled at one minute past 11:59 P.M., New York City Time, on January 15, 2020, (such date and time, the “Expiration Time”), and
was not extended. The Depositary has advised that, as of the Expiration Time, 103,394,298 Shares had been validly tendered and not properly withdrawn pursuant to the Offer, representing approximately 75.3% of the sum of (a) all Shares then
outstanding at the Expiration Date and (b) all Shares that ArQule would be required to issue upon the vesting (including vesting solely as a result of the consummation of the Offer), conversion, settlement or exercise of all then outstanding
warrants, options, benefit plans, obligations or securities convertible or exchangeable into Shares or other rights to acquire or be issued Shares ((including all then outstanding ArQule stock options and unexercised warrants to purchase Shares),
regardless of the conversion or exercise price or other terms and conditions thereof). Accordingly, the Minimum Condition has been satisfied. Purchaser has accepted, and has stated that it will as promptly as practicable on or after the Expiration
Date pay for, all Shares that were validly tendered and not validly withdrawn pursuant to the Offer.
Following expiration of the Offer and acceptance for payment of the Shares, Purchaser had ownership sufficient to effect the Merger under Section 251(h) of the DGCL, without a vote of stockholders of ArQule. Accordingly,
following completion of the Offer, Parent and Purchaser effected the Merger in accordance with Section 251(h) of the DGCL in which Purchaser merged with and into ArQule, with ArQule surviving the Merger and continuing as a wholly-owned subsidiary of
Parent. In the Merger, each Share outstanding (other than (i) Shares held in the treasury of ArQule or owned by Parent or Purchaser or any of their respective direct or indirect wholly-owned subsidiaries immediately prior to the Effective Time and
(ii) Shares as to which appraisal rights have been perfected in accordance with the DGCL) was cancelled and converted into the right to receive an amount of cash equal to the Offer Price, without interest and less any applicable tax withholding. The
Shares are expected to cease to trade on Nasdaq prior to the opening of business on January 16, 2020, and will be delisted from Nasdaq and deregistered under the Exchange Act.”
Item 12. Exhibits.
Item 12 of the Schedule TO is hereby amended and supplemented by adding the following exhibit thereto:
| Exhibit No. |
Description
|
| (a)(5)(A) |
Press release issued by Merck & Co., Inc., dated January 16, 2020.
|
SIGNATURES
After due inquiry and to the best knowledge and belief of the undersigned, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.
|
Argon Merger Sub, Inc.
|
|||
|
By:
|
/s/ Faye C. Brown
|
||
|
Name:
|
Faye C. Brown
|
||
|
Title:
|
Assistant Secretary
|
||
|
Merck Sharp & Dohme Corp.
|
|||
|
By:
|
/s/ Sunil A. Patel
|
||
|
Name:
|
Sunil A. Patel
|
||
|
Title:
|
Senior Vice President, Corporate Development
|
||
Date: January 16, 2020
Exhibit (a)(5)(A)
![]() |
News Release
|
FOR IMMEDIATE RELEASE
|
Media Contact:
|
Pamela Eisele
|
Investor Contacts:
|
Peter Dannenbaum
|
|
(267) 305-3558
|
(908) 740-1037
Courtney Ronaldo
(908) 740-6132
|
Merck Completes Acquisition of ArQule
KENILWORTH, N.J., Jan. 16, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all of the
outstanding shares of common stock of ArQule, Inc. (NASDAQ: ARQL) at a purchase price of $20.00 per share. As of the tender offer expiration, 103,394,298 shares of common stock of ArQule were validly tendered and not withdrawn from the tender offer,
representing approximately 75.3 percent of the outstanding common stock of ArQule on a fully diluted basis. All such shares have been accepted for payment in accordance with the terms of the tender offer, and Merck expects to promptly pay for such
shares.
Following the completion of the tender offer, Merck completed the acquisition of ArQule today through a merger of Merck’s wholly-owned subsidiary with and into ArQule in which all shares not tendered into
the offer were cancelled and converted into the right to receive cash equal to the $20.00 offer price per share, without interest, less any applicable tax withholding. At the completion of the merger, ArQule became a wholly-owned subsidiary of Merck.
The common stock of ArQule will no longer be listed or traded on the NASDAQ Global Select Market.
About Merck
For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life,
bringing forward medicines and vaccines for many of the world’s most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to
deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention
and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola. For more information, visit www.merck.com
and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes statements that are not statements of historical fact, or “forward-looking statements,” that are based upon the current beliefs and
expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the
forward-looking statements.
Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical
industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product
development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the
effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. Additional factors
that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2018 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC)
available at the SEC’s Internet site (www.sec.gov).
# # #
